Zileuton

Results: 17



#Item
1 Modificadores de Leucotrienos (Accolate®, Singulair ®, Zileuton ®)

Modificadores de Leucotrienos (Accolate®, Singulair ®, Zileuton ®)

Add to Reading List

Source URL: health.utah.gov

Language: Spanish - Date: 2011-01-20 17:51:30
    2Leukotriene Modifiers (Accolate®, Singulair®, Zileuton®) What are They?

    Leukotriene Modifiers (Accolate®, Singulair®, Zileuton®) What are They?

    Add to Reading List

    Source URL: health.utah.gov

    Language: English - Date: 2011-01-20 17:52:50
    3

    PDF Document

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    4Clin Pharmacokinet DOI[removed]s40262[removed]ORIGINAL RESEARCH ARTICLE Determination of an Optimal Dosing Regimen for Fexinidazole,

    Clin Pharmacokinet DOI[removed]s40262[removed]ORIGINAL RESEARCH ARTICLE Determination of an Optimal Dosing Regimen for Fexinidazole,

    Add to Reading List

    Source URL: www.dndi.org

    Language: English - Date: 2014-02-25 10:52:29
    5HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. JUXTAPID® (lomitapide) capsules, fo

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. JUXTAPID® (lomitapide) capsules, fo

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2014-08-12 12:33:10
    6U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    7Clinical Pharmacology Overview (NDA[removed], Mirabegron) Advisory Committee Presentation (April 5, 2012) Sayed (Sam) Al Habet, R.Ph., Ph.D.,

    Clinical Pharmacology Overview (NDA[removed], Mirabegron) Advisory Committee Presentation (April 5, 2012) Sayed (Sam) Al Habet, R.Ph., Ph.D.,

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    8Asthma Visit Checklist – Youths ≥ 12 Years of Age and Adults Patient Name FIGURE 4–7. ASSESSING ASTHMA CONTROL AND ADJUSTING T H E R A P Y I N Y O U T H S ≥1 2 Y E A R S O F A G E A N D A D U L T S

    Asthma Visit Checklist – Youths ≥ 12 Years of Age and Adults Patient Name FIGURE 4–7. ASSESSING ASTHMA CONTROL AND ADJUSTING T H E R A P Y I N Y O U T H S ≥1 2 Y E A R S O F A G E A N D A D U L T S

    Add to Reading List

    Source URL: www.pacnj.org

    Language: English - Date: 2014-03-21 11:42:52
    9Oregon Health Resources Commission

    Oregon Health Resources Commission

    Add to Reading List

    Source URL: www.oregon.gov

    Language: English - Date: 2014-07-15 14:00:33
    10Propranolol hydrochloride extended-release capsules Rx only DESCRIPTION Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino[removed]n

    Propranolol hydrochloride extended-release capsules Rx only DESCRIPTION Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino[removed]n

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2011-03-21 16:13:32